Sonnet BioTherapeutics has been granted a patent for compositions containing an albumin binding domain and a fusion partner, such as a cytokine, with increased serum half-life. The patent includes an IL-12 albumin binding domain fusion protein with a specific amino acid sequence. GlobalData’s report on Sonnet BioTherapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Sonnet BioTherapeutics, Peptide pharmacophores was a key innovation area identified from patents. Sonnet BioTherapeutics's grant share as of May 2024 was 8%. Grant share is based on the ratio of number of grants to total number of patents.
Il-12 albumin binding domain fusion protein
A recently granted patent (Publication Number: US12006361B2) discloses an IL-12 albumin binding domain fusion protein with a specific amino acid sequence (SEQ ID NO: 280). This fusion protein is designed to have enhanced binding capabilities due to the incorporation of the albumin binding domain. The patent also covers a nucleic acid encoding this fusion protein, an expression vector containing the nucleic acid, and a host cell that can express the fusion protein.
Furthermore, the patent includes a method for producing the IL-12 albumin binding domain fusion protein. This method involves culturing the host cell containing the nucleic acid under suitable conditions for protein expression and subsequently isolating the fusion protein. By detailing the specific sequence of the fusion protein and providing a method for its production, this patent offers a valuable contribution to the field of protein engineering and biotechnology. The incorporation of the albumin binding domain in the fusion protein could potentially enhance its stability and pharmacokinetic properties, making it a promising candidate for therapeutic applications.
To know more about GlobalData’s detailed insights on Sonnet BioTherapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
